Skip to main content

Table 1 Results of the effectiveness algorithm, overall and by index medication

From: Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Criterion Total (N = 7797), n (%) Adalimumab (n = 1899), n (%) Certolizumab pegol (n = 124), n (%) Etanercept (n = 4188), n (%) Golimumab (n = 170), n (%) Infliximab (n = 1416), n (%)
Criterion 1: PDC ≥0.8 for index TNFi 3362 (43.1%) 795 (41.9%) 35 (28.2%) 1721 (41.1%) 65 (38.2%) 746 (52.7%)
Criterion 2: Patients with no biologic switch or addition 6286 (80.6%) 1528 (80.5%) 99 (79.8%) 3339 (79.7%) 133 (78.2%) 1187 (83.8%)
Criterion 3: Patients with no addition of a new csDMARD 6705 (86.0%) 1604 (84.5%) 103 (83.1%) 3621 (86.5%) 137 (80.6%) 1240 (87.6%)
Criterion 4: Patients with no increase in index TNFi dose or frequency 7019 (90.0%) 1738 (91.5%) 116 (93.5%) 4151 (99.1%) 170 (100.0%) 844 (59.6%)
Criterion 5: Patients with no more than one glucocorticoid joint injection 6483 (83.1%) 1604 (84.5%) 96 (77.4%) 3591 (85.7%) 140 (82.4%) 1052 (74.3%)
Criterion 6: Patients with no increase in dose of oral glucocorticoid 6907 (88.6%) 1702 (89.6%) 112 (90.3%) 3734 (89.2%) 152 (89.4%) 1207 (85.2%)
Total number of patients with treatment response 2337 (30.0%) 586 (30.9%) 24 (19.4%) 1418 (33.9%) 56 (32.9%) 253 (17.9%)
  1. Abbreviations: csDMARD Conventional synthetic disease-modifying antirheumatic drug, PDC Proportion of days covered, TNFi Tumor necrosis factor inhibitors